RECURRENT HODGKIN LYMPHOMA
Clinical trials for RECURRENT HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Vitamin c boost: could high doses make chemo more effective for tough lymphomas?
Disease control Recruiting nowThis phase 2 trial tests whether adding high-dose intravenous vitamin C to standard chemotherapy can help treat blood cancers like lymphoma that have returned or not responded to treatment, as well as related conditions. About 80 adults will receive the combination to see if it i…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 08:55 UTC
-
Experimental combo aims to outsmart Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a pill that makes chemotherapy more effective)—is safe and can shrink tumors in people with B-cell lymphoma that has returned or stopped r…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
Immune boosting NK cells show promise in blood cancer trial
Disease control Recruiting nowThis study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Radioactive antibody cocktail aims to beat back stubborn hodgkin lymphoma
Disease control Recruiting nowThis study tests a new approach for Hodgkin lymphoma that has returned or not responded to treatment. It combines a radioactive antibody (yttrium-90 anti-CD25) with standard chemotherapy (BEAM) before a stem cell transplant. The goal is to kill cancer cells more effectively and i…
Matched conditions: RECURRENT HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:02 UTC